[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371709-105":59,"doc-detail-371709-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","hes1-in-malignant-tumors-from-molecular-mechanism-to-therapeutic-potential","Hes1 in malignant tumors - from molecular mechanism to therapeutic potential","","Recent research highlights the transcriptional regulator hairy and enhancer of split 1 (Hes1) as a key driver in malignant tumor occurrence and progression. Hes1 shows high expression across solid tumors and hematological malignancies, influencing immune cells, inflammatory signaling, and the tumor microenvironment to promote proliferation, invasion, metastasis, and treatment resistance. This review synthesizes current mechanistic insights, including Hes1 crosstalk with Notch, JAK/STAT, PI3K/AKT/mTOR, and Wnt/b-catenin pathways, and its regulation of immune checkpoint-related factors, ECM remodeling, and immune escape. It emphasizes Hes1’s links to clinical stage, prognosis, and drug resistance, and evaluates translational potential as a biomarker and therapeutic target, with a focus on tumor immunotherapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/hes1-in-malignant-tumors-from-molecular-mechanism-to-therapeutic-potential/371709/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/hes1-in-malignant-tumors-from-molecular-mechanism-to-therapeutic-potential/371709.png","ImageObject",300,407,{"name":92,"@type":93},"Pentious","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does Hes1 play in malignant tumors?","Question",{"text":112,"@type":113},"Hes1 contributes to tumor growth and progression by regulating molecular networks that affect immune cells, inflammatory factors, and the tumor microenvironment. It is also associated with proliferation, invasion, metastasis, and resistance to treatment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which signaling pathways interact with Hes1?",{"text":117,"@type":113},"Hes1 forms crosstalk with key pathways including Notch, JAK/STAT, PI3K/AKT/mTOR, and Wnt/β-catenin. These interactions help drive malignant transformation and progression.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is Hes1 considered promising for cancer therapy and immunotherapy?",{"text":121,"@type":113},"Hes1 can regulate immunosuppressive tumor microenvironment formation and immune escape through immune checkpoint-associated proteins and related processes such as ECM remodeling. Its expression levels correlate with tumor stage, prognosis, and drug resistance, supporting its translational potential as a biomarker and therapeutic target.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},371709,1791127896,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},1374404730887,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","TYPE Review  \nPUBLISHED 18 July 2025  \nDOI 10.3389/fimmu.2025.1585624  \nOPEN ACCESS  \nEDITED BY  \nJesse Haramati,  \nUniversity of Guadalajara, Mexico  \nREVIEWED BY  \nKousalya Lavudi,  \nThe Ohio State University, United States Peng Guo,  \nTianjin Cancer Hospital Airport Hospital, China  \n*CORRESPONDENCE  \nShuicai Huang  \n [522561556@qq.com](522561556@qq.com)[ ](522561556@qq.com)Zhenhuai Yang  \n[452847973@qq.com](452847973@qq.com)  \n†These authors have contributed equally to this work  \nRECEIVED 01 March 2025  \nACCEPTED 27 June 2025  \nPUBLISHED 18 July 2025  \nCITATION  \nZhang L, Zhang Q, Guo C, Ru Z, Yang Z, Geng Y, Yang J, Zhang D, Yang Z and Huang S (2025) Hes1 in malignant tumors: from molecular mechanism to therapeutic potential.  \nFront. Immunol. 16:1585624 .  \ndoi: 10.3389/fimmu.2025.1585624  \nCOPYRIGHT  \n© 2025 Zhang, Zhang, Guo, Ru, Yang, Geng, Yang, Zhang, Yang and Huang. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nHes1 in malignant tumors: from molecular mechanism to therapeutic potential  \nLiping Zhang †, Qian Zhang †, Cheng Guo, Zixin Ru, Zetian Yang, Yi Geng, Junjie Yang, Daigui Zhang, Zhenhuai Yang* and Shuicai Huang*  \nThe Afﬁliated Guangzhou Hospital of TCM of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China  \nThe occurrence and development of malignant tumors involve abnormalities in complex molecular regulatory networks, among which the abnormal activation of the transcriptional regulator hairy and enhancer of split 1 (Hes1) has attracted signiﬁcant attention in recent years and is closely associated with prognosis in various malignancies. Hes1 exhibits high expression in various solid tumors and hematological malignancies, where it participates in alterations involving diverse immune cells, inﬂammatory factors, and the immune microenvironment, thereby promoting tumor cell proliferation, invasion, metastasis, and resistance to treatment. Recent studies have widely investigated the potential of targeting Hes1 and inhibiting its expression as a cancer therapeutic strategy, although its precise mechanisms of action are not yet fully elucidated. Hes1 interacts with critical pathways including Notch, JAK/STAT, PI3K/AKT/mTOR, and Wnt/bcatenin. These interactions form complex crosstalk networks that drive malignant transformation and progression. Furthermore, Hes1 plays a central role in the formation of an immunosuppressive tumor microenvironment (TME) and immune escape by regulating the expression of immune checkpointassociated proteins, extracellular matrix (ECM) remodeling, and other processes, making it a highly promising therapeutic target. Notably, the expression level of Hes1 is signiﬁcantly correlated with tumor clinical stage, prognosis, and drug resistance. This review comprehensively introduces the mechanisms of Hes1 in the progression of malignant tumors, with a particular focus on discussing its application and underlying mechanisms in tumor immunotherapy. It integrates the latest clinical evidence and preclinical research perspectives. The goal is to highlight the translational potential of Hes1 as a novel biomarker and molecular target.  \nKEYWORDS  \nHes1, malignant tumors, signal transduction, therapeutic targets, tumor microenvironment  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nHes1 is a protein-coding gene that belongs to the basic helix loop-helix (bHLH) family. Hes1 was ﬁrst discovered in Drosophila, and subsequently found to be widely present in mammalian cells (1, 2) . The Hes1 protein, encoded by the Hes1 gene, contains 280 amino acids ","cbCaip6kGf2kohN3","https://ap.wps.com/l/cbCaip6kGf2kohN3","pdf",3515832,"English","# Introduction\n## Structure of Hes1 and its regulatory mechanisms\n### Molecular characterization of the Hes1 protein","[{\"question\":\"What role does Hes1 play in malignant tumors?\",\"answer\":\"Hes1 contributes to tumor growth and progression by regulating molecular networks that affect immune cells, inflammatory factors, and the tumor microenvironment. It is also associated with proliferation, invasion, metastasis, and resistance to treatment.\"},{\"question\":\"Which signaling pathways interact with Hes1?\",\"answer\":\"Hes1 forms crosstalk with key pathways including Notch, JAK/STAT, PI3K/AKT/mTOR, and Wnt/β-catenin. These interactions help drive malignant transformation and progression.\"},{\"question\":\"Why is Hes1 considered promising for cancer therapy and immunotherapy?\",\"answer\":\"Hes1 can regulate immunosuppressive tumor microenvironment formation and immune escape through immune checkpoint-associated proteins and related processes such as ECM remodeling. Its expression levels correlate with tumor stage, prognosis, and drug resistance, supporting its translational potential as a biomarker and therapeutic target.\"}]","Hes1 in malignant tumors - from molecular mechanism to therapeutic potential | PDF",1790192676,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d64f81b65bee002a777fe189be710709.webp",983,1389,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/96538bcd16ab841d86abf0f5cf4e1c57.webp",982,1388,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bfac91be0fb2a4a06c233d6b4bc6dc4b.webp",981,1386,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/623f288ee7bf33829dec89e7453e9008.webp",980,1385]